Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Pending VidaMed shareholder complaint that Medtronic's $326 mil., $7.91-per-share cash acquisition deal is inadequate is without merit, VidaMed says (1"The Gray Sheet," Dec. 10, 2001, p. 18). Filed Dec. 7 in the Delaware Court of Chancery, the complaint alleges that Medtronic was able to use its minority stake in the company to compel VidaMed's board to accept a less than fair acquisition price. The $7.91 per share deal represents a 40% premium to its pre-announcement close...

You may also be interested in...

FDA Commissioner Search: ACLA Head Sundwall Contacted By White House

American Clinical Laboratory Association President David Sundwall, MD, says he has been contacted twice recently by the White House to determine his interest in becoming the next FDA commissioner

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts